Provided by Tiger Trade Technology Pte. Ltd.

Corbus Pharmaceuticals

10.38
+0.54005.49%
Post-market: 10.15-0.2300-2.22%19:30 EDT
Volume:604.02K
Turnover:6.15M
Market Cap:200.76M
PE:-1.70
High:10.42
Open:9.97
Low:9.90
Close:9.84
52wk High:20.56
52wk Low:7.12
Shares:19.34M
Float Shares:17.42M
Volume Ratio:1.33
T/O Rate:3.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.0889
EPS(LYR):-5.9000
ROE:-95.58%
ROA:-53.00%
PB:1.96
PE(LYR):-1.76

Loading ...

Corbus Pharmaceuticals Holdings, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Corbus Pharmaceuticals Q2 EPS $(1.81) Misses $(1.26) Estimate

Benzinga Earnings
·
Aug 06

Corbus Q2 FY26 Net Loss Widens to $35.04 Million; Loss Per Share Increases to $1.81

Reuters
·
Aug 06

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 06

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 05

Corbus Pharma CMO Nicacio Leonardo Viana Files Initial Beneficial Ownership Statement

Reuters
·
Aug 05

Corbus reports last patient completes last visit in CANYON-1 trial

TIPRANKS
·
Aug 04

Corbus Says Phase 1b Canyon-1 Obesity Trial of CRB-913 Reaches Last Patient Last Visit

Reuters
·
Aug 04

Corbus Pharmaceuticals Announces Last Patient Last Visit in Canyon-1 Study of Crb-913 for the Treatment of Obesity

THOMSON REUTERS
·
Aug 04

Corbus Pharmaceuticals Holdings Inc Expected to Post a Loss of $1.26 a Share - Earnings Preview

Reuters
·
Jul 31

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Jul 30

Corbus Pharmaceuticals announces FDA clearance to initiate TEMPO-1 trial

TIPRANKS
·
Jul 28

Corbus Pharmaceuticals Announces FDA Clearance to Initiate Tempo-1 Registrational Study of Crb-701 in Patients with 2L Oropharyngeal Cancer

THOMSON REUTERS
·
Jul 28

Corbus Pharmaceuticals Holdings Inc: Expects to Initiate Enrollment in Tempo-1 in September 2026

THOMSON REUTERS
·
Jul 28

Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer

GlobeNewswire
·
Jul 28

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Jul 25

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 24

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Jul 23

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Jul 21

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 18